Published in Eur J Pharm Biopharm on September 01, 2004
Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev (2007) 1.91
Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J (2009) 1.37
Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J (2008) 1.02
The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J (2010) 1.01
Molecular dynamics simulations of large macromolecular complexes. Curr Opin Struct Biol (2015) 0.99
In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther (2008) 0.99
Fast disintegrating tablets: Opportunity in drug delivery system. J Adv Pharm Technol Res (2011) 0.99
Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement. J Pharm Bioallied Sci (2011) 0.93
Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharm (2013) 0.92
Stability-enhanced hot-melt extruded amorphous solid dispersions via combinations of Soluplus® and HPMCAS-HF. AAPS PharmSciTech (2015) 0.91
Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol (2012) 0.86
Preparation and in-vitro evaluation of indomethacin nanoparticles. Daru (2010) 0.85
A standardized mini paddle apparatus as an alternative to the standard paddle. AAPS PharmSciTech (2008) 0.85
Preparation, Characterization and Stability Studies of Glassy Solid Dispersions of Indomethacin using PVP and Isomalt as carriers. Iran J Basic Med Sci (2012) 0.82
Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studies. Eur J Clin Pharmacol (2010) 0.82
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One (2013) 0.81
Controlled release hydrophilic matrix tablet formulations of isoniazid: design and in vitro studies. AAPS PharmSciTech (2008) 0.81
Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance. Antimicrob Agents Chemother (2017) 0.80
Helicobacter pylori infection and drugs malabsorption. World J Gastroenterol (2014) 0.80
Planar microdevices for enhanced in vivo retention and oral bioavailability of poorly permeable drugs. Adv Healthc Mater (2014) 0.80
Preparation and characterization of celecoxib dispersions in soluplus(®): comparison of spray drying and conventional methods. Iran J Pharm Res (2015) 0.79
In vitro-in vivo correlation of efavirenz tablets using GastroPlus®. AAPS PharmSciTech (2013) 0.79
Development and characterization of a new oral dapsone nanoemulsion system: permeability and in silico bioavailability studies. Int J Nanomedicine (2012) 0.79
Automated selection of compounds with physicochemical properties to maximize bioavailability and druglikeness. J Chem Inf Model (2010) 0.79
Design and Evaluation of Ethyl Cellulose Based Matrix Tablets of Ibuprofen with pH Modulated Release Kinetics. Indian J Pharm Sci (2008) 0.78
Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls. AAPS J (2015) 0.77
Effect of cyclodextrin complexation on the aqueous solubility and solubility/dose ratio of praziquantel. AAPS PharmSciTech (2009) 0.76
A menthol-based solid dispersion technique for enhanced solubility and dissolution of sulfamethoxazole from an oral tablet matrix. AAPS PharmSciTech (2014) 0.76
An investigation into the influence of experimental conditions on in vitro drug release from immediate-release tablets of levothyroxine sodium and its relation to oral bioavailability. AAPS PharmSciTech (2011) 0.76
Triethanolamine stabilization of methotrexate-β-cyclodextrin interactions in ternary complexes. Int J Mol Sci (2014) 0.75
Pediatric Biopharmaceutical Classification System: Using Age-Appropriate Initial Gastric Volume. AAPS J (2016) 0.75
Recrystallization of commercial carbamazepine samples-a strategy to control dissolution variability. Pharmaceutics (2012) 0.75
Preparation and characterization of celecoxib solid dispersions; comparison of poloxamer-188 and PVP-K30 as carriers. Iran J Basic Med Sci (2014) 0.75
Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection. Antimicrob Agents Chemother (2015) 0.75
Using a single tablet daily to treat latent tuberculosis infection in Brazil: bioequivalence of two different isoniazid formulations (300 mg and 100 mg) demonstrated by a sensitive and rapid high-performance liquid chromatography-tandem mass spectrometry method in a randomised, crossover study. Mem Inst Oswaldo Cruz (2015) 0.75
Formulation and in vivo evaluation of orally disintegrating tablets of clozapine/hydroxypropyl-β-cyclodextrin inclusion complexes. AAPS PharmSciTech (2013) 0.75
Impact of vibration and agitation speed on dissolution of USP prednisone tablets RS and various IR tablet formulations. AAPS PharmSciTech (2015) 0.75
Statistics on BCS classification of generic drug products approved between 2000 and 2011 in the USA. AAPS J (2012) 0.75
Pharmacokinetic study of furosemide incorporated PLGA microspheres after oral administration to rat. Iran J Basic Med Sci (2016) 0.75
Study on biopharmaceutics classification and oral bioavailability of a novel multikinase inhibitor NCE for cancer therapy. Int J Mol Sci (2014) 0.75
In vivo Evaluation of Self Emulsifying Drug Delivery System for Oral Delivery of Nevirapine. Indian J Pharm Sci (2014) 0.75
Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study. PLoS One (2015) 0.75
Computational investigation on the host-guest inclusion process of norfloxacin into β-cyclodextrin. J Mol Model (2016) 0.75
Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res (2008) 1.47
Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res (2006) 1.37
A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem (2004) 1.12
Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur J Pharm Biopharm (2007) 1.09
The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci (2010) 1.01
A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm Res (2003) 1.00
Can the USP paddle method be used to represent in-vivo hydrodynamics? J Pharm Pharmacol (2003) 0.98
Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol (2004) 0.96
Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm (2010) 0.95
Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Clin Pharmacokinet (2006) 0.95
Influence of hydrodynamics and particle size on the absorption of felodipine in labradors. Pharm Res (2002) 0.95
Dissolution improvement of four poorly water soluble drugs by cogrinding with commonly used excipients. Eur J Pharm Biopharm (2007) 0.94
Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms. J Pharm Sci (2011) 0.94
Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol (2009) 0.92
Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm Res (2002) 0.92
Biowaiver monographs for immediate release solid oral dosage forms: metronidazole. J Pharm Sci (2011) 0.89
Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm (2009) 0.89
New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin. Eur J Pharm Biopharm (2012) 0.88
Designing biorelevant dissolution tests for lipid formulations: case example--lipid suspension of RZ-50. Eur J Pharm Biopharm (2007) 0.86
Cogrinding enhances the oral bioavailability of EMD 57033, a poorly water soluble drug, in dogs. Eur J Pharm Biopharm (2007) 0.86
Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. Eur J Pharm Biopharm (2010) 0.86
Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J Pharm Sci (2011) 0.85
Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database. J Med Chem (2007) 0.85
Use of physiologically based pharmacokinetic models coupled with pharmacodynamic models to assess the clinical relevance of current bioequivalence criteria for generic drug products containing Ibuprofen. J Pharm Sci (2014) 0.85
Application of a ternary HP-β-CD-complex approach to improve the dissolution performance of a poorly soluble weak acid under biorelevant conditions. Int J Pharm (2012) 0.84
Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach. Eur J Pharm Biopharm (2013) 0.84
Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur J Pharm Sci (2009) 0.83
Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. J Pharm Pharmacol (2009) 0.83
Biowaiver monographs for immediate-release solid oral dosage forms: primaquine phosphate. J Pharm Sci (2011) 0.83
Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir. Eur J Pharm Biopharm (2011) 0.83
Media to simulate the postprandial stomach I. Matching the physicochemical characteristics of standard breakfasts. J Pharm Pharmacol (2004) 0.82
Development and validation of a physiology-based model for the prediction of oral absorption in monkeys. Pharm Res (2007) 0.82
Promoting GMP implementation: developing training materials for the international audience. Qual Assur (2003) 0.82
Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm Res (2006) 0.82
The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance. J Pharm Sci (2014) 0.80
Biowaiver monographs for immediate-release solid oral dosage forms: ketoprofen. J Pharm Sci (2012) 0.79
Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing. J Pharm Sci (2010) 0.79
Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state. Eur J Pharm Biopharm (2013) 0.79
Use of the BioDis to generate a physiologically relevant IVIVC. J Control Release (2008) 0.79
Particle diffusional layer thickness in a USP dissolution apparatus II: a combined function of particle size and paddle speed. J Pharm Sci (2008) 0.78
Biowaiver monographs for immediate release solid oral dosage forms: efavirenz. J Pharm Sci (2012) 0.78
Online monitoring of dissolution tests using dedicated potentiometric sensors in biorelevant media. Eur J Pharm Biopharm (2010) 0.78
Characterization of the ascending colon fluids in ulcerative colitis. Pharm Res (2010) 0.77
Biorelevant media to simulate fluids in the ascending colon of humans and their usefulness in predicting intracolonic drug solubility. Pharm Res (2010) 0.76
Biowaiver monographs for immediate release solid oral dosage forms: amodiaquine hydrochloride. J Pharm Sci (2012) 0.76
Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. Eur J Pharm Biopharm (2010) 0.76
An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: case example dantrolene. Eur J Pharm Biopharm (2012) 0.76
Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs. Case example: itraconazole. Eur J Pharm Biopharm (2012) 0.76
Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation. J Pharm Sci (2013) 0.76
Characterization of a new solvate of risedronate. J Pharm Sci (2010) 0.75
Biowaiver monographs for immediate release solid oral dosage forms: levofloxacin. J Pharm Sci (2011) 0.75
Biowaiver monographs for immediate release solid oral dosage forms: piroxicam. J Pharm Sci (2013) 0.75
Biowaiver monograph for immediate-release solid oral dosage forms: bisoprolol fumarate. J Pharm Sci (2013) 0.75
In vitro tools for evaluating novel dosage forms of poorly soluble, weakly basic drugs: case example ketoconazole. J Pharm Sci (2013) 0.75
Biowaiver monographs for immediate-release solid oral dosage forms: Zidovudine (azidothymidine). J Pharm Sci (2013) 0.75
A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies. J Pharm Sci (2013) 0.75
Biowaiver monograph for immediate-release solid oral dosage forms: acetylsalicylic acid. J Pharm Sci (2012) 0.75
Convenient and rapid determination of cimetidine in human plasma using perchloric acid-mediated plasma protein precipitation and high-performance liquid chromatography. Biomed Chromatogr (2007) 0.75
The biowaiver procedure: its application to antituberculosis products in the WHO prequalification programme. J Pharm Sci (2010) 0.75
Biowaiver monograph for immediate-release solid oral dosage forms: fluconazole. J Pharm Sci (2014) 0.75
Prediction of blood-brain barrier penetration of poorly soluble drug candidates using surface activity profiling. Eur J Pharm Biopharm (2010) 0.75
Composition and physicochemical properties of fasted-state human duodenal and jejunal fluid: a critical evaluation of the available data. J Pharm Sci (2014) 0.75
Biowaiver monographs for immediate-release solid oral dosage forms: stavudine. J Pharm Sci (2011) 0.75
Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products. J Pharm Pharmacol (2009) 0.75
Biowaiver monographs for immediate-release solid oral dosage forms: quinine sulfate. J Pharm Sci (2011) 0.75
Biowaiver monographs for immediate-release solid oral dosage forms: codeine phosphate. J Pharm Sci (2014) 0.75
Validation of Dissolution Testing with Biorelevant Media: an OrBiTo study. Mol Pharm (2017) 0.75